8DZ Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€492.19K
Enterprise Value€1.32
Total Cash (Recent Filing)€60.85K
Total Debt (Recent Filing)€394.63K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementThe substantial gross-margin improvement indicates better product economics or cost control. If maintained, it can improve operating leverage and provide a stronger base for returning to profitability, although revenue stabilization remains necessary.
Manageable LeverageModerate leverage and positive equity provide financial flexibility compared with a highly indebted or deficit-equity structure. This reduces balance-sheet pressure over the next several months, though continued losses could weaken equity if not reversed.
Recently Positive Cash FlowThe shift to positive operating and free cash flow is a meaningful improvement from negative levels in FY2023–FY2024. It suggests some ability to fund operations internally, but the modest scale requires continued revenue and margin stabilization.
Bears Say
Sharp Revenue ContractionA sharply shrinking top line limits scale benefits, weakens operating leverage, and makes fixed costs harder to absorb. Sustained contraction could offset gross-margin gains and constrain investment, distribution, and the path to durable profitability.
Persistent LossesOngoing net and operating losses show that improved gross margin has not yet translated into a viable earnings model. Continued losses can consume equity, restrict access to capital, and reduce the company’s ability to scale without external funding.
Weak Cash ConversionPositive cash flow remains modest relative to revenue and is declining versus the prior period. This limits confidence in its durability, particularly while losses persist, and suggests the business has limited internal funding capacity for expansion or unexpected needs.
Pascal Biosciences Inc News
8DZ FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is €492.19K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 48 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in DE:8DZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―